This company has been marked as potentially delisted and may not be actively trading. NantKwest (NK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NK vs. PRME, IKT, PLX, IZTC, CRTX, ZIVO, JATT, CVM, CLDI, and FNCHShould you be buying NantKwest stock or one of its competitors? The main competitors of NantKwest include Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), JATT Acquisition (JATT), CEL-SCI (CVM), Calidi Biotherapeutics (CLDI), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector. NantKwest vs. Its Competitors Prime Medicine Inhibikase Therapeutics Protalix BioTherapeutics Invizyne Technologies Cortexyme ZIVO Bioscience JATT Acquisition CEL-SCI Calidi Biotherapeutics Finch Therapeutics Group Prime Medicine (NYSE:PRME) and NantKwest (NASDAQ:NK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Do institutionals and insiders have more ownership in PRME or NK? 70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 9.4% of NantKwest shares are held by institutional investors. 22.9% of Prime Medicine shares are held by company insiders. Comparatively, 71.7% of NantKwest shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, PRME or NK? Prime Medicine has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, NantKwest has a beta of 2.61, meaning that its stock price is 161% more volatile than the S&P 500. Which has stronger earnings & valuation, PRME or NK? NantKwest has lower revenue, but higher earnings than Prime Medicine. NantKwest is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrime Medicine$3.85M141.28-$198.13M-$1.61-2.51NantKwest$40K6,478.69-$65.79M-$0.70-3.39 Do analysts rate PRME or NK? Prime Medicine currently has a consensus target price of $9.25, suggesting a potential upside of 128.96%. Given Prime Medicine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Prime Medicine is more favorable than NantKwest.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75NantKwest 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is PRME or NK more profitable? Prime Medicine has a net margin of 0.00% compared to NantKwest's net margin of -76,658.58%. NantKwest's return on equity of -56.06% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Prime MedicineN/A -107.87% -74.97% NantKwest -76,658.58%-56.06%-46.93% Does the media prefer PRME or NK? In the previous week, Prime Medicine had 16 more articles in the media than NantKwest. MarketBeat recorded 16 mentions for Prime Medicine and 0 mentions for NantKwest. Prime Medicine's average media sentiment score of 0.67 beat NantKwest's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media. Company Overall Sentiment Prime Medicine Positive NantKwest Neutral SummaryPrime Medicine beats NantKwest on 10 of the 17 factors compared between the two stocks. Get NantKwest News Delivered to You Automatically Sign up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NK vs. The Competition Export to ExcelMetricNantKwestBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$259.15M$267.92M$5.49B$9.52BDividend YieldN/AN/A4.73%4.09%P/E Ratio-3.34N/A28.7823.81Price / Sales6,478.69327.48372.2066.04Price / CashN/A22.4435.4557.96Price / Book1.9310.418.275.54Net Income-$65.79M-$106.40M$3.25B$259.28M NantKwest Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKNantKwestN/A$2.37-3.7%N/A-48.6%$259.15M$40K-3.34160Gap DownHigh Trading VolumePRMEPrime Medicine3.7469 of 5 stars$4.53-0.9%$9.25+104.2%-22.2%$609.27M$3.85M-2.21234News CoverageInsider TradeGap DownIKTInhibikase Therapeutics2.0854 of 5 stars$1.93+2.7%$6.50+236.8%+10.9%$143.48MN/A-0.726News CoveragePLXProtalix BioTherapeutics2.2289 of 5 stars$1.58+3.9%$15.00+849.4%+36.2%$125.78M$59.76M-12.15200News CoverageGap UpIZTCInvizyne TechnologiesN/A$9.25flatN/AN/A$57.83MN/A0.0029Positive NewsGap UpCRTXCortexymeN/A$1.90+0.5%N/A+127.2%$57.29MN/A-0.6455News CoverageZIVOZIVO BioscienceN/A$13.25flatN/A+18.7%$50.58M$15.85K-2.7210JATTJATT AcquisitionN/A$1.72-9.9%N/A-62.8%$29.67MN/A0.003High Trading VolumeCVMCEL-SCI1.2111 of 5 stars$5.27+21.1%N/A-72.6%$28.04MN/A-10.9843Positive NewsShort Interest ↑High Trading VolumeCLDICalidi Biotherapeutics0.2029 of 5 stars$0.70-2.4%N/A-64.7%$25.91MN/A0.0038Short Interest ↑Gap DownFNCHFinch Therapeutics GroupN/A$12.39+0.8%N/A+556.3%$19.90MN/A-1.40190Gap Down Related Companies and Tools Related Companies PRME Alternatives IKT Alternatives PLX Alternatives IZTC Alternatives CRTX Alternatives ZIVO Alternatives JATT Alternatives CVM Alternatives CLDI Alternatives FNCH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NK) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NantKwest, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NantKwest With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
